Effective palliative treatment of recurrent soft tissue sarcoma in a dog using imatinib mesylate (Gleevec®)

https://doi.org/10.17221/34/2018-VETMEDCitation:Kim G.H., Kim J.H. (2018): Effective palliative treatment of recurrent soft tissue sarcoma in a dog using imatinib mesylate (Gleevec®). Veterinarni Medicina, 63: 532-536.
download PDF

A 14-year-old neutered female Yorkshire terrier presented with a rapidly growing gluteal mass. There was a history of surgical resection of a mass diagnosed as a grade two soft tissue sarcoma in the same region a year earlier. The second mass was surgically excised and histopathologically diagnosed as grade two soft tissue sarcoma. A further relapse occurred six months after the second surgery. On that occasion, the dog was treated with metronomic chemotherapy consisting of cyclophosphamide and piroxicam, which failed to adequately control the disease and the mass increased 2.5-fold in size in three weeks. Imatinib treatment was started, after which there was a 62% reduction in the size of the mass. The patient has remained in partial remission for five months. To the authors’ knowledge, this is the first report on the use of imatinib to treat canine soft tissue sarcoma. Imatinib might be a useful treatment for soft tissue sarcoma that recurs after surgical resection.

References:
Arora A. (2005): Role of Tyrosine Kinase Inhibitors in Cancer Therapy. Journal of Pharmacology and Experimental Therapeutics, 315, 971-979  https://doi.org/10.1124/jpet.105.084145
 
Bray J. P. (2016): Soft tissue sarcoma in the dog - part 1: a current review. Journal of Small Animal Practice, 57, 510-519  https://doi.org/10.1111/jsap.12556
 
Bray J. P. (2017): Soft tissue sarcoma in the dog - Part 2: surgical margins, controversies and a comparative review. Journal of Small Animal Practice, 58, 63-72  https://doi.org/10.1111/jsap.12629
 
Buchdunger Elisabeth, O'Reilley Terence, Wood Jeanette (2002): Pharmacology of imatinib (STI571). European Journal of Cancer, 38, S28-S36  https://doi.org/10.1016/S0959-8049(02)80600-1
 
Chao Celia, Al-Saleem Tahseen, Brooks John J., Rogatko Andr�, Kraybill William G., Eisenberg Burton (2001): Vascular Endothelial Growth Factor and Soft Tissue Sarcomas: Tumor Expression Correlates With Grade. Annals of Surgical Oncology, 8, 260-267  https://doi.org/10.1007/s10434-001-0260-9
 
Dernell William S., Withrow Stephen J., Kuntz Charles A., Powers Barbara E. (1998): Principles of treatment for soft tissue sarcoma. Clinical Techniques in Small Animal Practice, 13, 59-64  https://doi.org/10.1016/S1096-2867(98)80029-7
 
Dorn ER (1976): Epidemiology of canine and feline tumors. Journal of the American Animal Hospital Association 12, 307–312.
 
Elmslie R.E., Glawe P., Dow S.W. (2008): Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue Sarcomas. Journal of Veterinary Internal Medicine, 22, 1373-1379  https://doi.org/10.1111/j.1939-1676.2008.0179.x
 
Ettinger Susan N. (2003): Principles of treatment for soft-tissue sarcomas in the dog. Clinical Techniques in Small Animal Practice, 18, 118-122  https://doi.org/10.1053/svms.2003.36628
 
Forrest Lisa J., Chun Ruthanne, Adams WM., Cooley A. James, Vail David M. (2000): Postoperative Radiotherapy for Canine Soft Tissue Sarcoma. Journal of Veterinary Internal Medicine, 14, 578-582  https://doi.org/10.1111/j.1939-1676.2000.tb02279.x
 
Fujiki M, Aucejo F, Kim R (2011): General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver International 31, 1081–1089.
 
Gortzak E, Azzarelli A, Buesa J, Bramwell V.H.C, van Coevorden F, van Geel A.N, Ezzat A, Santoro A, Oosterhuis J.W, van Glabbeke M, Kirkpatrick A, Verweij J (2001): A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. European Journal of Cancer, 37, 1096-1103  https://doi.org/10.1016/S0959-8049(01)00083-1
 
Hohenberger P, Wysocki WM (2008): Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choose? Oncologist 13, 175–186.
 
Liptak JM, Forrest LJ (2013): 21 Soft tissue sarcoma. In: Withrow SJ, Vail DM, Page RL (eds): Withrow and MacEwen’s Small Animal Clinical Oncology. 5th edn. Elsevier, St Louis. 356–380.
 
London Cheryl A. (2009): Tyrosine Kinase Inhibitors in Veterinary Medicine. Topics in Companion Animal Medicine, 24, 106-112  https://doi.org/10.1053/j.tcam.2009.02.002
 
London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM (2003): Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 9, 2755–2768.
 
Mutsaers Anthony J. (2009): Metronomic Chemotherapy. Topics in Companion Animal Medicine, 24, 137-143  https://doi.org/10.1053/j.tcam.2009.03.004
 
Shchemelinin I, Sefc L, Necas E (2006): Protein kinase inhibitors. Folia Biologica (Praha) 52, 137–148.
 
STEFANELLO DAMIANO, MORELLO EMANUELA, ROCCABIANCA PAOLA, IUSSICH SELINA, NASSUATO CLAUDIA, MARTANO MARINA, SQUASSINO CHIARA, AVALLONE GIANCARLO, ROMUSSI STEFANO, BURACCO PAOLO (2008): Marginal Excision of Low-Grade Spindle Cell Sarcoma of Canine Extremities: 35 Dogs (19962006). Veterinary Surgery, 37, 461-465  https://doi.org/10.1111/j.1532-950X.2008.00408.x
 
Stroobants S., Goeminne J., Seegers M., Dimitrijevic S., Dupont P., Nuyts J., Martens M., van den Borne B., Cole P., Sciot R., Dumez H., Silberman S., Mortelmans L., van Oosterom A. (2003): 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). European Journal of Cancer, 39, 2012-2020  https://doi.org/10.1016/S0959-8049(03)00073-X
 
Theilen GH, Madewell BR (1979): Tumours of the skin and subcutaneous tissues. In: Theilen GH, Madewell BR (eds): Veterinary Cancer Medicine. Lea and Febiger, Philadelphia. 123–191.
 
download PDF

© 2020 Czech Academy of Agricultural Sciences | Prohlášení o přístupnosti